期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Comparative Proteomic Analysis of B. henselae Houston and B. henselae Marseille by Two-dimensional Gel Electrophoresis 被引量:3
1
作者 SU-QING ZHAO YAN-FEI CAI ZHEN-YU ZHU 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2005年第5期341-344,共4页
To compare the protein difference between B. henselae Houston and B. henselae Marseille by two-dimensional gel electrophoresis. Method Protein samples were prepared by vorterx, ultrasonic treatment, and centrifugation... To compare the protein difference between B. henselae Houston and B. henselae Marseille by two-dimensional gel electrophoresis. Method Protein samples were prepared by vorterx, ultrasonic treatment, and centrifugation. Protein concentrations were determined by Bradford method. Protein difference was compared by the first IEF and the second SDS-polyacrylamide gel electrophoresis. Results Protein concentrations in samples of Bartonella henselae Houston and Bartonella henselae Marseille were 2.117 μg/μL and 2.200 μg/μL respectively. Sample protein of 40 μg for IPG strips loading was perfect. The results of 2-DE in pH 4 to 7 IPG strips showed that the total protein spots of Bartonella henselae Houston and Bartonella henselae Marseille were 375 and 379 respectively, 95% of the spots were the same between the two strains of Bartonella henselae. Conclusion The procedure of 2-DE may prove successful for the proteomic analysis of Bartonella henselae. Bartonella henselae Houston and Bartonella henselae Marseille are different genotypes. 展开更多
关键词 PROTEIN B.henselae Two-dimensional gel electrophoresis
下载PDF
心包积液的分子学分析:7年经验
2
作者 Levy P.-Y. Fournier P.-E. +2 位作者 Charrel R. D. Raoult 吴晓燕 《世界核心医学期刊文摘(心脏病学分册)》 2007年第1期51-52,共2页
目的:心包渗出液的病原学检测结果往往为阴性,作者对心包渗出液进行系统分析以减少心包炎被归为特发性的数量,并评价了该做法的益处。方法与结果:对106例心包积液的样本除了进行组织病理学检验,还系统分析心包渗出液和活检标本,采用病... 目的:心包渗出液的病原学检测结果往往为阴性,作者对心包渗出液进行系统分析以减少心包炎被归为特发性的数量,并评价了该做法的益处。方法与结果:对106例心包积液的样本除了进行组织病理学检验,还系统分析心包渗出液和活检标本,采用病原培养和分子学分析进行细菌、真菌和病毒鉴定。分别有40例和9例患者通过临床和无创性检查得出病原学诊断。 展开更多
关键词 分子学 渗出液 活检标本 病原学检测 真菌感染 组织病理学 肺炎链球菌 新型隐球菌 分子技术 治疗者
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部